Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPsDARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs
VS
AUROBINDO PHARMA LTDAUROBINDO PHARMA LTD
DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs

DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs

N/A

Last Update: 22/04/2026

View Profile
Between 750 and 799
https://www.darzalexhcp.com/
753/1000Fair

Please see Important Safety Information below in the pinned post and at https://www.darzalexhcp.com/ISI.   This product information is intended for US Healthcare Professionals only.   DARZALEX® and DARZALEX FASPRO® are products of Janssen Biotech, Inc., and are not asso...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:0
Subsidiaries:16
12-month incidents
0
Known data breaches
0
Attack type number
0
AUROBINDO PHARMA LTD

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, 500032, IN

Last Update: 03/04/2026

View Profile
Between 750 and 799
https://www.aurobindo.com/
778/1000Fair

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, brand...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:14,862
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Ranges Comparison

Based On Specific Ai Models Category
DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs

DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
AUROBINDO PHARMA LTD

AUROBINDO PHARMA LTD

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2026.

Incidents

Incident History - DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs (X = Date, Y = Severity)

DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs cyber incidents detection timeline including parent company and subsidiaries.

R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs

DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs

Incidents
No explicit notable incidents reported.
AUROBINDO PHARMA LTD

AUROBINDO PHARMA LTD

Incidents
No explicit notable incidents reported.

FAQ

Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one has the best AI Cybersecurity Score ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one has experienced more cyber incidents in the past ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one has experienced more cyber incidents this year ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one has experienced at least one ransomware attack ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one has experienced at least one data breach ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one has experienced at least one targeted cyberattack ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one has experienced at least one vulnerability ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one holds the most compliance certifications ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one holds the fewest compliance certifications ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one has the most subsidiaries ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs company and AUROBINDO PHARMA LTD company, which one has the largest number of employees ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs and AUROBINDO PHARMA LTD, which company holds both SOC 2 Type 1 certifications ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs and AUROBINDO PHARMA LTD, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs or AUROBINDO PHARMA LTD ?
Which company is PCI DSS compliant - DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs or AUROBINDO PHARMA LTD ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs and AUROBINDO PHARMA LTD, which company complies with HIPAA regulations for healthcare data ?
Between DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs and AUROBINDO PHARMA LTD, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-16197
SUMMARY

A security vulnerability has been detected in Sipeed PicoClaw up to 0.2.9. The affected element is the function handleMessageReceive of the file pkg/channels/feishu/feishu_64.go of the component Group Message Handler. Such manipulation leads to missing authorization. The attack can be launched remotely. The exploit has been disclosed publicly and may be used. The reported GitHub issue was closed automatically due to inactivity.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8
CVE-2026-16196
SUMMARY

A weakness has been identified in Sipeed PicoClaw up to 0.2.9. Impacted is the function isPrivateOrRestrictedIP of the file pkg/tools/integration/web.go of the component web_fetch. This manipulation causes server-side request forgery. The attack can be initiated remotely. The exploit has been made available to the public and could be used for attacks. Patch name: 2efbe5d560e7ed9bc5209c203dc4aa6ecdbc7405. To fix this issue, it is recommended to deploy a patch.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8
CVE-2026-16195
SUMMARY

A security flaw has been discovered in Sipeed PicoClaw up to 0.2.9. This issue affects the function dispatchIncoming of the file pkg/channels/wecom/wecom.go of the component Group Message Handler. The manipulation results in incorrect authorization. It is possible to launch the attack remotely. The exploit has been released to the public and may be used for attacks. The reported GitHub issue was closed automatically due to inactivity.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8
CVE-2026-10130
SUMMARY

QueryWeaver contains an authentication bypass vulnerability that allows unauthenticated attackers to obtain valid session tokens for existing accounts by submitting a signup request with a known victim email address. The signup route unconditionally creates and links a new token to the matching Identity via a Cypher MERGE operation before checking whether the email belongs to an existing account, causing the server to return a valid authenticated session token for the victim's identity without requiring any prior credentials or user interaction.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 8.2)
CVSS3
Base Score: 8.2
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:L/A:N
CVSS4
Base Score: 8.8
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
4.2
EXPLOITABILITY
3.9
CVE-2026-16194
SUMMARY

A vulnerability was determined in zhayujie CowAgent up to 2.1.1. This affects the function WebFetch.execute of the file agent/tools/web_fetch/web_fetch.py. Executing a manipulation of the argument url can lead to server-side request forgery. The attack may be performed from remote. The exploit has been publicly disclosed and may be utilized. Upgrading to version 2.1.2 is able to mitigate this issue. This patch is called ea47f3097eed4f8295c4cb3d76ecb97e0f43d632. It is recommended to upgrade the affected component. The vendor was contacted early, responded in a very professional manner and quickly released a fixed version of the affected product.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8